Genetic engineering concept. Medical science. Scientific Laboratory.

Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea™ RNAP, Progresses Towards GMP Linea™ IVT Production Start

March 18, 2024

Read More email

Applied DNA to Showcase Linea™ DNA and Linea™ IVT Platforms

March 14, 2024

Read More email

Applied DNA Announces Joint Development Agreement to Integrate Linea™ IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow

December 14, 2023

Read More email

APDN Announces Receipt of Linea™ DNA Follow-On Order for Cancer Diagnostic Application

November 28, 2023

Read More email

Applied DNA Extends Application of Linea™ IVT Platform to saRNA (self-amplifying mRNA)

November 16, 2023

Read More email

Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea™ DNA Platform

November 9, 2023

Read More email

APDN Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals

September 14, 2023

Read More email

APDN Advances Commercialization of Linea™ IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

September 6, 2023

Read More email

LineaRx to Participate in Upcoming mRNA Industry Conferences

July 18, 2023

Read More email

APDN Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT™ Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach

July 13, 2023

Read More email

APDN Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date

March 29, 2023

Read More email

APDN Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines

January 5, 2023

Read More email

APDN to Establish N. America’s 1st Enzymatic Large-Scale cGMP DNA Manufacturing Capacity in New York

October 24, 2022

Read More email

APDN Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date

October 10, 2022

Read More email

LineaRx Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets

September 30, 2022

Read More email

APDN and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications

September 8, 2022

Read More email

LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)

August 10, 2022

Read More email

LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development

July 25, 2022

Read More email

LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit

July 22, 2022

Read More email

APDN Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

June 29, 2022

Read More email

Positive Preclinical Data for LinearDNA™ as Novel Cancer Vaccine Strategy

June 7, 2022

Read More email

Spindle Biotech Research Collaboration on mRNA Production System

March 14, 2022

Read More email

Beefing Up Cancer Treatments, With A Vaccine In Sight

February 18, 2022

Read More email

APDN and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

February 17, 2022

Read More email

LineaRx Receives Repeat Orders for LinearDNA

November 15, 2021

Read More email

Research Publication Demonstrates Utility of APDN’s LinearDNA™ in Non-Viral CAR T Manufacturing Systems

November 9, 2021

Read More email

Research Publication Demonstrates Utility of APDN’s LinearDNA™ in Non-Viral CAR T Manufacturing

November 9, 2021

Read More email

APDN Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch

June 7, 2021

Read More email

APDN, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

May 6, 2021

Read More email

Clinical Trial to Evaluate LinearDNA COVID-19 Vaccine Candidate for Felines

March 2, 2021

Read More email

APDN Develops Linear DNA Veterinary COVID-19 Vaccine

February 2, 2021

Read More email

APDN, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate

November 30, 2020

Read More email

APDN Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications

November 2, 2020

Read More email

APDN and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate

September 16, 2020

Read More email

APDN Positions LinearDNA™ Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing

August 17, 2020

Read More email

APDN and Takis Report Positive Preclinical Results from LineaDNA™ Vaccine Candidates for COVID-19

July 17, 2020

Read More email

APDN Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates

June 9, 2020

Read More email

APDN Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program

June 8, 2020

Read More email

APDN to Participate in Maxim Group’s COVID-19 Virtual Conference Series on May 27

May 21, 2020

Read More email

APDN and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals

May 4, 2020

Read More email

Italian Biotech Startup Racing To Develop A Coronavirus Vaccine

April 21, 2020

Read More email

APDN High-Sensitivity and High-Throughput COVID-19 Diagnostic Kit Enters Validation Process in Partnership with Stony Brook University Hospital

April 21, 2020

Read More email

LI Biotech Speeds COVID-19 Vaccine Candidates To Italy

April 15, 2020

Read More email

APDN Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing

April 15, 2020

Read More email

APDN to Speak on COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5

April 14, 2020

Read More email

APDN Ships LinearDNA™ to Another Development Customer

March 26, 2020

Read More email

APDN Secures Top-20 Pharmaceutical Manufacturer as Drug Development Customer

March 20, 2020

Read More email

APDN Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design a High Sensitivity Diagnostic Kit for Virus Detection

March 19, 2020

Read More email

APDN COVID-19 Collaboration Partner Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-Clinical Models

March 18, 2020

Read More email

Stony Brook firm working on coronavirus vaccine

March 3, 2020

Read More email

Applied DNA, Takis Biotech design four Covid-19 vaccine candidates

March 3, 2020

Read More email

Applied DNA Speeds Coronavirus Vaccines Toward Tests

March 2, 2020

Read More email

APDN Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed

March 2, 2020

Read More email

Applied DNA To Speed Up Coronavirus Countermeasures

February 13, 2020

Read More email

Applied DNA, Takis Biotech partner on coronavirus vaccine

February 11, 2020

Read More email

LineaRx and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV

February 7, 2020

Read More email

LineaRx, Inc. Signs Licensing Agreement with LifeSensors

January 13, 2020

Read More email

APDN to Hold Investment Community Meetings During the JP Morgan 38th Annual Healthcare Conference and Present at the Biotech Showcase 2020

January 10, 2020

Read More email

LineaRx signs agreement with TYME Technologies

November 29, 2019

Read More email

LineaRx Signs Agreement with TYME Technologies for Functional ICTC Assay Services in Pancreatic Cancer Trial

November 26, 2019

Read More email

APDN Reports 14 Development Customers for its Linear DNA Manufacturing Platform

November 25, 2019

Read More email

iCTC Platform Shows Superior Correlation over PSA as a Biomarker

October 1, 2019

Read More email

Linear DNA Combo Shows Punch In Cancer Fight

September 20, 2019

Read More email

LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

September 19, 2019

Read More email

For Applied DNA, New Blood — And A Shot In The Arm

August 14, 2019

Read More email

Medicare Coverage of CAR T-Cell Therapy Holds Positive Implications for LineaRx

August 12, 2019

Read More email

LineaRx Acquires Cancer Cell Assets and Intellectual Property of Vitatex

August 9, 2019

Read More email

LineaRx Acquires Assets and Intellectual Property of Vitatex

August 8, 2019

Read More email

LineaRx Receives Multiple Orders for Linear DNA for Use in Therapeutic Development

July 1, 2019

Read More email

LineaRx to Support Therapy Development for Neurodegenerative Diseases

June 26, 2019

Read More email

LineaRx Anticipates Expansion in Diagnostics Market

May 21, 2019

Read More email

LineaRx Achieves Higher Expression and Survival Rates in Human T Cells

April 29, 2019

Read More email

Linear DNA Crosses the Line between Tags and Therapeutics

April 9, 2019

Read More email

LineaRx Achieves Anti-CD19 Expression in Human CAR T Cells via Plasmid-Free Platform

April 8, 2019

Read More email

LineaRx and Takis/Evvivax Progress Linear DNA for Use as Cancer Vaccine Candidates

March 1, 2019

Read More email

LineaRx to Announce DNA Vaccine Preclinical Data and Efficacy of In-Licensed CAR T Therapy

December 4, 2018

Read More email

LineaRx Provides Cost and Quality Advantages to Technogenetics

November 7, 2018

Read More email

At LineaRX, Putting The Horsepower Behind The CAR T

October 17, 2018

Read More email

Non-Viral, Plasmid-Free CAR T-Manufacturing Platform Begins Preclinicals

October 16, 2018

Read More email

LineaRx Licenses CAR T Drug Candidate, Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform

October 16, 2018

Read More email

LineaRx Secures New RNA Therapeutics Customers for Contract Research Services

October 1, 2018

Read More email

LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines

September 20, 2018

Read More email

LineaRx Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines

September 20, 2018

Read More email

With New Spinoff, Biotech Goes All-In On DNA Sales

September 19, 2018

Read More email

APDN Forms Subsidiary, LineaRx, to Develop DNA for Biotherapeutics

September 18, 2018

Read More email

APDN Presenting Linear DNA for Gene Therapy at Boston Immuno-Oncology Summit

August 27, 2018

Read More email